Jeffrey Scharfstein

Selected Transactions:

• Aetna in its sale to CVS Health (NYSE – CVS) for $69 billion and related DOJ-mandated divestiture*
• Silicon Labs (Nasdaq – SLAB) in the sale of its infrastructure and automotive business for $2.75 billion
• Luminex Corporation, a US publicly traded company, in its sale to an Italian publicly traded company for $1.8 billion
• Silver Spike Acquisition Corp., a special purpose acquisition vehicle, in its $1.5 billion combination with WMH Holdings*
• Emerson Electric (NYSE – EMR) in its $3.1 billion acquisition of the valves and controls business of Pentair and a related FTC-mandated divestiture*
• Symphony Technology Group-led consortium in its $2.1 billion acquisition of the RSA software security business from Dell Technologies* 
• A financial holding company in its sale of its ownership interest in an asset manager for consideration in excess of $2 billion
• Alimera Sciences (NASDAQ: ALIM) in its pending sale to ANI Pharmaceuticals for approximately $430 million
• Lionheart III Corp, a special purpose acquisition company, in its US$360 million merger with Security Matters Limited, a publicly traded company on the Australian Securities Exchange
• Q2 (Nasdaq – QTWO) in its acquisition of ClickSWITCH
• RateGenius in its business combination with AUTOPAY and formation of The Savings Group
• Safeguard Global in its acquisition of Global Upside Corporation
• BoomTown in its sale to Inside Real Estate
• Netwrix in its strategic investment from Centerbridge Partners
• Tailwind Capital and its portfolio companies in connection with various private equity acquisitions and investments*
• ORIX Capital Partners and Lightyear Capital in connection with various private equity acquisitions and investments*
• ECI Telecom Group in its merger with Ribbon Communications*
• Signify Health (NYSE – SGFY) in connection with various strategic matters, including acquisitions and commercial arrangements*
• Pattern Energy in connection with its acquisition of renewable energy projects and related joint ventures*
• Various financial advisor engagements, including representing Morgan Stanley, Dyal and Evercore as advisors to Bristol Myers Squibb in connection with its $74 billion acquisition of Celgene*

*Experience handled prior to joining DLA Piper